The Cambridge-based Spirea Ltd. has developed a smart polymer platform for the controlled delivery of drug combinations that maximizes the clinical impact of medicines. Their antibody-drug conjugate is intended to revolutionize cancer treatment by directing more drug payload to the tumor cell, resulting in an increase in therapeutic effect while substantially reducing debilitating side effects. This flexible approach allows physicians to provide well-tolerated medicines for the treatment of a wide range of cancers. Spirea's innovative technology enables a pipeline of superior and differentiated antibody drug conjugates for the treatment of a range of solid tumors, advancing a new generation of antibody-targeted cancer treatments with significantly better efficacy and safety profiles.